Fig. 1 · Structure

Documents & Downloads

Imatinib (Gleevec)

Cat. No. A10259 CAS 152459-95-5

PDGFR inhibitor

Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.

In Stock

Publications for Imatinib

7 publications citing this product

  1. Rong Zhang, .et al. , Gene, 2024, Jan 30:893:147917 PMID: 37866664
  2. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  3. Takafumi Shima, .et al. , Oncol Rep, 2022, 47: 7 PMID: 34738628
  4. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  5. BM Duggan, .et al. , Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
  6. Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961
  7. Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Imatinib binds within the ATP-binding cleft of the isolated ABL kinase domain and stabilizes an inactive activation-loop conformation. The full imatinib–ABL complex was resolved at 2.1 Å; this structural result concerns a murine kinase-domain construct. [1]

In a cell-free ABL assay, imatinib inhibited the dephosphorylated enzyme with an IC50 of approximately 100 nM, while phosphorylated ABL was only weakly inhibited under the same conditions. This value is phosphorylation-state and assay dependent. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PDGFR (Cell-free assay) 100 nM
c-Kit (M-07e cells) 100 nM
v-Abl (Cell-free assay) 600 nM

Cellular Effect

Cell Line Activity Value Description Reference
786-0 GI50 16 μM Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay [PMID: 32942186]
A10 IC50 162 nM Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay [PMID: 27502700]
A2780 IC50 4.8 x 10 Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay [PMID: 19301902]
A2780 IC50 8.9 μM Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay [PMID: 29684708]
A-431 IC50 3.1 x 10 Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay [PMID: 19301902]
A498 GI50 21.98 μM Growth inhibition of human A498 cells measured after 48 hrs by SRB assay [PMID: 32942186]
A549 IC50 > 25 μM Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay [PMID: 30562697]
A549 IC50 15.5 μM Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay [PMID: 19301902]
A549 GI50 24.49 μM Growth inhibition of human A549 cells measured after 48 hrs by SRB assay [PMID: 32942186]
A549 IC50 4.56 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 28525838]
ACHN GI50 25.23 μM Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay [PMID: 32942186]
ASPC1 IC50 4.4 x 10 Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay [PMID: 19301902]
BaF3 IC50 > 1 μM Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay [PMID: 26195136]
BaF3 GI50 > 10 μM Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay [PMID: 31250638]
BaF3 GI50 > 10 μM Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 > 10 μM Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 > 10 μM Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 31046271]
BaF3 GI50 > 10 μM Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 > 10 μM Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]
BaF3 GI50 > 10 μM Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay [PMID: 30317026]

20 records · Scroll to view more

Imatinib (Gleevec) Research Summary

This section summarizes 3 in vitro studies of Imatinib (Gleevec) from 2 published references.

Imatinib (Gleevec) In Vitro Studies

In primary CML stem-enriched and progenitor populations, 5 µM imatinib for 4 hours suppressed phosphotyrosine and BCR-ABL substrate phosphorylation under serum/cytokine-free conditions. Residual phosphorylation remained. Phospho-CRKL flow cytometry did not reproduce the immunoblot response in primary cells, emphasizing the importance of assay choice. These acute signaling endpoints do not establish elimination of CML stem cells. [2]

Imatinib binding to the inactive ABL kinase domain

Biochemical assay · Isolated murine c-Abl kinase domain (residues 229–515), unphosphorylated; X-ray complex with synthesized STI-571 [1]

The full imatinib molecule occupies the ATP-binding cleft and stabilizes an inactive activation-loop conformation. PD173955 provides a structural comparator with a different activation-loop conformation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diffraction resolution of ABL:STI-571 structureResolution 2.1 Å[1]
ATP-site occupancy and activation-loop conformationStructural observation Imatinib binds the ATP-binding site and stabilizes a closed, inactive activation loop.[1]

Literature-Reported Treatment Conditions

Method
In vitro co-complex formation for X-ray crystallography.
Vehicle
DMSO used for inhibitor stock.
Reported limits
Salt/counterion and product lot are not specified. This is a structural experiment, not a cellular treatment-dose experiment.
Methods and source locations

Compound reported in the paper: Imatinib; Compound label in the paper: STI-571

Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.

Table 1; Figures 1a and 3; pp. 4237–4240, structural Methods and Results

Diffraction resolution of ABL:STI-571 structure: X-ray crystallography; Table 1 reports resolution range 30–2.1 Å. — Table 1, AblK:STI571 column; Results, Overall Features of the Structures, p. 4238

ATP-site occupancy and activation-loop conformation: Crystal structure and interaction analysis; PD173955 complex used as comparator. — Figure 3A/B left; Results, Structure of Abl Kinase Domain Bound to STI-571, pp. 4238–4240

ABL inhibition depends on activation-loop phosphorylation

Biochemical assay · Purified murine ABL catalytic domain, compared in phosphorylated and phosphatase-dephosphorylated states [1]

In the same coupled assay, imatinib inhibited dephosphorylated ABL more strongly than phosphorylated ABL; PD173955 inhibited both states.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of dephosphorylated ABL-catalyzed peptide phosphorylationIC50 approximately 100 nM[1]
Inhibition of phosphorylated ABL compared with dephosphorylated ABLQualitative comparison Phosphorylated ABL was only weakly inhibited by imatinib over the tested range.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiment; Figure 6A plots STI-571 concentrations in µM. The approximately 100 nM value is an assay IC50, not a fixed treatment concentration.
Method
Cell-free peptide phosphorylation assay comparing ABL phosphorylation states.
Vehicle
4% DMSO in the assay.
Co-treatment
No therapeutic combination. Phosphatase treatment defines the dephosphorylated enzyme condition; PD173955 tested separately as comparator.
Reported limits
Assay duration and replicate/error-bar semantics are not specified in the read kinase-assay methods or Figure 6 caption; no exact IC50 is inferred from the curve.
Methods and source locations

Compound reported in the paper: Imatinib; Compound label in the paper: STI-571

Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.

Figure 6 and caption; Kinase Assays, p. 4238; Results, pp. 4241–4242

Inhibition of dephosphorylated ABL-catalyzed peptide phosphorylation: Continuous NADH-coupled spectrophotometric kinase assay at 340 nm; 0.5 mM ATP, 0.5 mM peptide substrate, 10 nM ABL, 30°C and 4% DMSO. — Figure 6A; Results, p. 4242; Kinase Assays, p. 4238

Inhibition of phosphorylated ABL compared with dephosphorylated ABL: Same kinase assay; phosphorylated versus dephosphorylated ABL, with PD173955 as state-insensitive comparator. — Figure 6A/B and caption; Results, pp. 4241–4242

Acute BCR-ABL pathway inhibition in primary CML stem/progenitor cells

Cell-based study · Primary lineage-negative cells from newly diagnosed chronic-phase CML patients, including CD34+CD38– and CD133+ stem-enriched populations and CD34+CD38+ progenitors; normal marrow controls and BCR-ABL-expressing cell-line comparators [2]

Four-hour imatinib treatment suppressed phosphotyrosine and BCR-ABL substrate phosphorylation in stem-enriched and progenitor populations. Residual signal and an assay-specific phospho-CRKL flow-cytometry limitation prevent equating these readouts with complete abolition of all kinase activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular phosphotyrosine in immunophenotypically defined primary CML populationsPhosphorylation suppression Reduced in CD34+CD38+, CD34+CD38– and CD133+ populations after 5 µM imatinib for 4 h. Residual signal remained above matched-isotype background.[2]
Phospho-CRKL signal in primary CML CD34+ cellsSignal reduction 75%[2]
Agreement of phospho-CRKL readouts in primary CML cellsAssay limitation Phospho-CRKL FACS did not reproduce the inhibition pattern observed by immunoblot in primary CML CD34+ cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM imatinib in the principal acute comparisons; Figure 1C also compares an imatinib concentration range.
Exposure duration
4 h
Method
In vitro exposure under serum/cytokine-free conditions, followed by phosphotyrosine FACS or substrate-phosphorylation immunoblot; corrected immunocytochemical population labels considered.
Co-treatment
Imatinib alone; no cytokine cocktail in the selected acute comparisons.
Reported limits
Vehicle and reagent salt/supplier/lot are not specified in the read acute assay description. No therapeutic dose or salt conversion inferred.
Methods and source locations

Compound reported in the paper: Imatinib; Compound label in the paper: IM

Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.

Figures 1 and 2A–C; corrected Figure 2D (erratum); Supplemental Figure 1; Results, Imatinib inhibits BCR-ABL in CML stem and progenitor cells; acute assay Methods

Cellular phosphotyrosine in immunophenotypically defined primary CML populations: Intracellular phosphotyrosine FACS; untreated and matched-isotype controls, phenotypically matched normal cells and BCR-ABL-expressing cell lines. Figure 1A: MFI ± SEM, n=10 CML and n=3 normal; Figure 1C: 3 independent CML samples. — Figure 1A–C and caption; Results, first acute target-inhibition subsection

Phospho-CRKL signal in primary CML CD34+ cells: Immunoblot comparison after 4 h imatinib treatment; total CRKL and actin controls. The text reports 75% suppression but also says normal levels were not restored. — Figure 2A and acute target-inhibition Results, paragraph beginning Total phosphotyrosine levels

Agreement of phospho-CRKL readouts in primary CML cells: Within-paper comparison of phospho-CRKL flow cytometry, phospho-CRKL immunoblot and phosphotyrosine flow cytometry. — Supplemental Figure 1A–C and caption; acute target-inhibition Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 152459-95-5
Applications PDGFR inhibitor
Formula C29H31N7O
Molecular Weight 493.6
Synonyms STI571; Glivec; Gleevec
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (56.72 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Imatinib (Gleevec) Research References

  1. [1] Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer research (2002). PMID: 12154025 Source material
  2. [2] Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. The Journal of clinical investigation (2011). PMID: 21157039 DOI: 10.1172/jci35721 Source material

Publications

7 publications citing this product

  1. Rong Zhang, .et al. , Gene, 2024, Jan 30:893:147917 PMID: 37866664
  2. Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  3. Takafumi Shima, .et al. , Oncol Rep, 2022, 47: 7 PMID: 34738628
  4. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  5. BM Duggan, .et al. , Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
  6. Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961
  7. Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277

Added to your cart

View Cart Checkout
Loading...